At a glance

What is sermorelin?

Sermorelin is the shortest fully active fragment of human GHRH, the hypothalamic hormone that signals the pituitary to release growth hormone. Unlike most peptides in the wellness market, it has a prior approval history: It was marketed as Geref for assessing growth hormone secretion and for treating growth failure in children. That product was discontinued, and sermorelin is now supplied mainly as a compounded preparation and promoted for anti-aging and body composition in adults.

How does it work?

Sermorelin is a GHRH-receptor agonist. It binds the same pituitary receptor as natural GHRH and stimulates pulsatile growth hormone release, which in turn raises IGF-1. It is shorter-acting than CJC-1295 but works through the same pathway. The adult wellness claims rest on this growth-hormone-raising pharmacology rather than on demonstrated outcomes. This describes the proposed mechanism, separate from whether it produces the marketed results.

Is it FDA-approved?

Not currently. The table below sets out sermorelin's regulatory status.

What does the research show?

The historical human data relate to its original approved uses, not the adult wellness market. Sermorelin's role in diagnosing growth hormone capacity and treating pediatric growth hormone deficiency was established, and physiology studies confirm that GHRH signaling augments nocturnal growth hormone release (here¹). There are no controlled trials showing that sermorelin improves muscle, fat, recovery, or aging in healthy adults; those uses are extrapolated from its effect on hormone levels.

Frequently asked questions

What is sermorelin and how is it different from human growth hormone?

Sermorelin is a synthetic 29-amino-acid GHRH analog that stimulates the pituitary to produce growth hormone naturally, rather than supplying GH directly. It works by binding to GHRH receptors on the anterior pituitary and triggering pulsatile GH release, while the hypothalamus retains the ability to reduce that signal via somatostatin when levels are sufficient², which is thought to limit excess GH; no head-to-head safety trials compare it with HGH. In contrast, exogenous HGH bypasses the pituitary entirely. Sermorelin requires an intact, responsive pituitary to produce a GH response.

What does the GHRH class research show about visceral fat reduction?

Tesamorelin trials showed visceral fat reduction with pulsatile GH stimulation; the controlled data come from tesamorelin, which binds the same receptor as sermorelin. In a 412-patient RCT, tesamorelin 2 mg SC daily cut visceral adipose tissue 15.2% at 26 weeks³, versus a 5.0% increase with placebo (p<0.001). A pooled analysis of two phase 3 trials⁴ (N=806) showed a ~15.4% VAT reduction versus placebo at 26 weeks, sustained through 52 weeks without clinically meaningful glucose changes. A 12-month RCT in 60 abdominally obese adults with reduced GH secretion found a net 19% VAT reduction versus placebo⁵, plus a net 37 mg/dL triglyceride reduction. These are tesamorelin data; there are no controlled trials showing that sermorelin improves fat in healthy adults.

How does GHRH signaling affect IGF-1 levels?

GHRH receptor activation stimulates pulsatile GH release, which drives IGF-1 secretion from the liver , IGF-1 is the primary downstream marker of GH axis function. In seven healthy men aged 65-78, the GH response to a GHRH test was blunted⁶ compared with young men, and 100 mcg IV GHRH-40 given every 2 days for 12 days significantly restored that response. A retrospective study reported a related finding: in 14 men on testosterone therapy given sermorelin with GHRP-2 and GHRP-6 for a mean of 134 days, IGF-1 rose from 159.5 to 239.0 ng/mL⁷, about a 50% increase (p<0.0001).

Does sermorelin affect sleep quality?

GHRH has been studied for effects on slow-wave sleep; evidence comes from GHRH studies rather than sermorelin-specific trials. In controlled studies, GHRH administration increased slow-wave sleep from 14.0% to 20.2%⁸ of total sleep time (a 44% relative increase) in seven healthy men, and another study in healthy young men found an almost 10-fold increase in slow-wave sleep⁹ when GHRH was given during late sleep. In older adults (mean age 69.3), GHRH reduced nocturnal awakenings¹⁰, though its effects were much smaller than in younger adults, which the researchers interpreted as reduced GHRH efficacy with aging. However, these studies used IV GHRH administration; direct randomized controlled trials specifically examining subcutaneous sermorelin's effects on sleep are not available.

Is sermorelin FDA-approved, and what is its regulatory status?

Sermorelin is not currently FDA-approved for any use. It was approved by the FDA in 1990 as a diagnostic agent and in 1997 as indicated for idiopathic growth hormone deficiency in children, but the manufacturer discontinued it in 2008. FDA later determined that the discontinued GEREF products were not withdrawn from sale for reasons of safety or effectiveness¹¹. No current DailyMed label exists for sermorelin. It is available through compounding, though its status remains under ongoing FDA review.

What does the research show about sermorelin and lean muscle mass?

Tesamorelin trials reported increases in lean muscle mass; there are no controlled trials showing that sermorelin improves muscle in healthy adults. In a secondary analysis of 341 adults with HIV (tesamorelin responders versus placebo; 26 weeks), truncal muscle density increased by 1.56-4.86 Hounsfield units¹² across four muscle groups vs placebo (all p<0.005), and lean muscle area increased 0.64-1.08 cm² across four truncal groups. A meta-analysis of five RCTs¹³ of tesamorelin versus placebo in adults with HIV found lean body mass increased by a mean 1.42 kg (95% CI 1.13-1.71, p<0.001). These findings are from tesamorelin trials, not sermorelin.

What is somatopause and why does GH decline with age?

Somatopause is the gradual reduction in growth hormone secretion beginning in early adult life¹⁴. Research points to more than one contributor. One study found evidence of reduced hypothalamic GHRH output in older men¹⁵, contributing to their lower GH, while GH responses to injected GHRH did not differ between young and older men. Another found that in men aged 65-78, the pituitary responded less to a GHRH test⁶ than in young men; repeated GHRH doses restored that response, so the reduced sensitivity appears at least partly reversible. GHRH also had weaker effects on sleep and cortisol¹⁰ in older adults, which the researchers interpreted as reduced GHRH efficacy with aging. Together, these findings suggest that both reduced hypothalamic signaling and a less responsive pituitary play a role.

More for bones & muscles